John Mendelsohn - Net Worth and Insider Trading
John Mendelsohn Net Worth
The estimated net worth of John Mendelsohn is at least $7,565 dollars as of 2024-11-13. John Mendelsohn is the Director of Merrimack Pharmaceuticals Inc and owns about 500 shares of Merrimack Pharmaceuticals Inc (MACK) stock worth over $7,565. Details can be seen in John Mendelsohn's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John Mendelsohn has not made any transactions after 2012-12-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of John Mendelsohn
John Mendelsohn Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John Mendelsohn owns 1 companies in total, including Merrimack Pharmaceuticals Inc (MACK) .
Click here to see the complete history of John Mendelsohn’s form 4 insider trades.
Insider Ownership Summary of John Mendelsohn
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MACK | Merrimack Pharmaceuticals Inc | 2012-12-14 | director |
John Mendelsohn Latest Holdings Summary
John Mendelsohn currently owns a total of 1 stock. John Mendelsohn owns 500 shares of Merrimack Pharmaceuticals Inc (MACK) as of December 14, 2012, with a value of $7,565.
Latest Holdings of John Mendelsohn
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MACK | Merrimack Pharmaceuticals Inc | 2012-12-14 | 500 | 15.13 | 7,565 |
Holding Weightings of John Mendelsohn
John Mendelsohn Form 4 Trading Tracker
According to the SEC Form 4 filings, John Mendelsohn has made a total of 0 transactions in Merrimack Pharmaceuticals Inc (MACK) over the past 5 years. The most-recent trade in Merrimack Pharmaceuticals Inc is the acquisition of 500 shares on December 14, 2012, which cost John Mendelsohn around $33,150.
Insider Trading History of John Mendelsohn
- 1
John Mendelsohn Trading Performance
GuruFocus tracks the stock performance after each of John Mendelsohn's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John Mendelsohn is -6.25%. GuruFocus also compares John Mendelsohn's trading performance to market benchmark return within the same time period. The performance of stocks bought by John Mendelsohn within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John Mendelsohn's insider trading performs compared to the benchmark.
Performance of John Mendelsohn
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -4.73 | | | | | |
| Relative Return to S&P 500(%) | -8.77 | | | | | |
John Mendelsohn Ownership Network
Ownership Network List of John Mendelsohn
Ownership Network Relation of John Mendelsohn
John Mendelsohn Owned Company Details
What does Merrimack Pharmaceuticals Inc do?
Who are the key executives at Merrimack Pharmaceuticals Inc?
John Mendelsohn is the director of Merrimack Pharmaceuticals Inc. Other key executives at Merrimack Pharmaceuticals Inc include director & other: See Remarks Eric Andersen , director & President Gary L Crocker , and director & other: See Remarks Noah G. Levy .
Merrimack Pharmaceuticals Inc (MACK) Insider Trades Summary
Over the past 18 months, John Mendelsohn made no insider transaction in Merrimack Pharmaceuticals Inc (MACK). Other recent insider transactions involving Merrimack Pharmaceuticals Inc (MACK) include a net purchase of 446,418 shares made by Eric Andersen , and a net purchase of 4,000 shares made by Gary L Crocker .
In summary, during the past 3 months, insiders sold 0 shares of Merrimack Pharmaceuticals Inc (MACK) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Merrimack Pharmaceuticals Inc (MACK) were sold and 450,418 shares were bought by its insiders, resulting in a net purchase of 450,418 shares.
Merrimack Pharmaceuticals Inc (MACK)'s detailed insider trading history can be found in Insider Trading Tracker table.
Merrimack Pharmaceuticals Inc Insider Transactions
John Mendelsohn Mailing Address
Above is the net worth, insider trading, and ownership report for John Mendelsohn. Currently GuruFocus does not have mailing address information for John Mendelsohn.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
